H.I.G. Capital Actualité
H.I.G. Capital Launches H.I.G. Healthcare Royalty & Credit
MIAMI – March 19, 2014 - H.I.G. Capital, a leading global investment firm with over $15 billion of capital under management, announced today the launch of H.I.G. Healthcare Royalty & Credit. H.I.G. Healthcare Royalty & Credit will focus on making income generating investments in the healthcare sector, including pharmaceuticals, biotechnology, specialty pharmaceuticals, medical devices and products, diagnostics, and services. H.I.G. Healthcare Royalty & Credit is ideally positioned to meet the diverse royalty-based and credit requirements of companies in the pharmaceutical, biotechnology, and medical device industries.
H.I.G. Healthcare Royalty & Credit is a joint effort between H.I.G. BioVentures, which invests in a broad range of life science companies across multiple sectors and stages of development and has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer; and H.I.G. WhiteHorse, which provides senior and subordinated debt for refinancings, growth capital, acquisitions, buyouts, and balance sheet recapitalizations and has deep credit expertise.
Tony Tamer, Managing Partner at H.I.G. Capital commented, “The H.I.G. Healthcare Royalty & Credit investment strategy will benefit from the synergies between the two seasoned investment teams at H.I.G. BioVentures and H.I.G. WhiteHorse. As one of the few firms with a leading life sciences platform, as well as a highly experienced credit team, H.I.G. Healthcare Royalty & Credit is differentiated in the marketplace and brings broad expertise to a wide variety of situations.”
About H.I.G. Capital
H.I.G. is a leading global private equity investment firm with more than $15 billion of equity capital under management. Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, New York, and San Francisco in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, and Rio de Janeiro, H.I.G. specializes in providing capital to small and medium-sized companies with attractive growth potential. H.I.G. invests in management-led buyouts and recapitalizations of profitable and well managed manufacturing or service businesses. Since its founding in 1993, H.I.G. has invested in and managed more than 200 companies worldwide. The firm’s current portfolio includes more than 80 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
About H.I.G. BioVentures
H.I.G. BioVentures is the dedicated life-science investment affiliate of H.I.G. Capital. H.I.G. BioVentures invests in a broad range of life sciences opportunities across sectors and stages, principally in companies developing therapeutic drugs, medical devices, and diagnostics for significant unmet medical needs. With approximately $400 million in committed capital, H.I.G. BioVentures invests $5 million to $40 million per company over the life of an investment. For more information, please refer to the H.I.G. BioVentures website at www.higbio.com.
About H.I.G. Whitehorse
H.I.G. WhiteHorse is the credit affiliate of H.I.G. Capital. H.I.G. WhiteHorse provides debt financing to middle market companies in the U.S. and Europe. H.I.G. WhiteHorse has a broad investment mandate and provides senior and subordinated debt for refinancings, growth capital, acquisitions, buyouts, and balance sheet recapitalizations. Credit facilities typically range from $15 to $100 million for companies with revenues of $50 million or more. For more information, please refer to the H.I.G. Whitehorse website at www.higwhitehorse.com.